Related Experiment Video
Updated: May 13, 2025
Preparation of Mouse Pituitary Immunogen for the Induction of Experimental Autoimmune Hypophysitis
Published on: December 17, 2010
Immune Checkpoint Inhibitor-Mediated Aseptic Meningitis and Hypophysitis
Pavel Bleik1, Panisara Fangsaard1, Nataliya Yuklyaeva1
1Department of Internal Medicine, Bassett Medical Center, Cooperstown, New York, USA.
Immune checkpoint inhibitors have revolutionized cancer treatment, yet their use is associated with unique and sometimes unpredictable immune-related adverse events. We present a case of a 67-year-old female with renal cell cancer treated with ipilimumab and nivolumab who developed aseptic meningitis and hypophysitis. This case highlights the challenges in managing immune-related adverse events and underscores the need for vigilance in monitoring patients receiving ICIs.
Immune checkpoint inhibitors have revolutionized cancer treatment, yet their use is associated with unique and sometimes unpredictable immune-related adverse events. We present a case of a 67-year-old female with renal cell cancer treated with ipilimumab and nivolumab who developed aseptic meningitis and hypophysitis. This case highlights the challenges in managing immune-related adverse events and underscores the need for vigilance in monitoring patients receiving ICIs.
